Lynch & Associates Has Lifted By $368,125 Its J P Morgan Chase & Co (JPM) Stake; Last Week Eagle Pharmaceuticals, Inc. (EGRX) Coverage

February 20, 2018 - By Marie Mckinney

Among 4 analysts covering Eagle Pharma (NASDAQ:EGRX), 3 have Buy rating, 1 Sell and 0 Hold. Therefore 75% are positive. Eagle Pharma had 21 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets with “Outperform” on Tuesday, May 10. The stock of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has “Neutral” rating given on Monday, June 20 by Mizuho. The firm earned “Buy” rating on Sunday, November 5 by RBC Capital Markets. The firm has “Buy” rating given on Wednesday, December 9 by Mizuho. Piper Jaffray maintained Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) rating on Wednesday, July 29. Piper Jaffray has “Overweight” rating and $119 target. Piper Jaffray maintained the shares of EGRX in report on Tuesday, January 30 with “Buy” rating. The firm earned “Outperform” rating on Thursday, November 3 by RBC Capital Markets. The stock has “Buy” rating by Mizuho on Wednesday, October 26. Mizuho maintained the shares of EGRX in report on Wednesday, August 9 with “Sell” rating. The firm earned “Buy” rating on Monday, October 2 by RBC Capital Markets. See Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) latest ratings:

30/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $79.0 Maintain
18/12/2017 Broker: Mizuho Rating: Sell New Target: $37.0 Maintain
05/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $81.0 Maintain
26/10/2017 Broker: Mizuho Rating: Sell New Target: $37.0 Maintain
02/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $81.0 Maintain
01/09/2017 Broker: RBC Capital Markets Rating: Buy New Target: $81.0 Maintain

Lynch & Associates increased J P Morgan Chase & Co (JPM) stake by 22.57% reported in 2017Q3 SEC filing. Lynch & Associates acquired 3,875 shares as J P Morgan Chase & Co (JPM)’s stock declined 6.04%. The Lynch & Associates holds 21,047 shares with $2.01 million value, up from 17,172 last quarter. J P Morgan Chase & Co now has $392.76B valuation. The stock decreased 0.72% or $0.83 during the last trading session, reaching $114.68. About 13.21M shares traded. JPMorgan Chase & Co. (NYSE:JPM) has risen 33.74% since February 20, 2017 and is uptrending. It has outperformed by 17.04% the S&P500.

The stock decreased 0.11% or $0.07 during the last trading session, reaching $64.78. About 197,546 shares traded. Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has risen 79.40% since February 20, 2017 and is uptrending. It has outperformed by 62.70% the S&P500.

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company has market cap of $966.62 million. The firm offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It has a 10.37 P/E ratio. The Company’s product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer.

Among 33 analysts covering JPMorgan Chase & Co (NYSE:JPM), 18 have Buy rating, 2 Sell and 13 Hold. Therefore 55% are positive. JPMorgan Chase & Co had 110 analyst reports since July 21, 2015 according to SRatingsIntel. Vetr upgraded JPMorgan Chase & Co. (NYSE:JPM) on Tuesday, September 1 to “Buy” rating. On Thursday, October 6 the stock rating was downgraded by Sandler O’Neill to “Hold”. The rating was maintained by Bank of America with “Buy” on Friday, October 13. The firm has “Buy” rating by RBC Capital Markets given on Friday, January 12. The stock has “Hold” rating by Credit Suisse on Thursday, January 11. On Wednesday, September 7 the stock rating was maintained by Nomura with “Neutral”. The firm has “Hold” rating given on Tuesday, September 26 by Deutsche Bank. The rating was maintained by BMO Capital Markets on Friday, October 6 with “Hold”. The firm has “Buy” rating given on Wednesday, February 24 by Jefferies. The stock has “Hold” rating by Keefe Bruyette & Woods on Thursday, December 21.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: